Johnson & Johnson agreed to acquire Halda Therapeutics for $3.05 billion in cash to add Halda’s RIPTAC-derived precision oncology portfolio to J&J’s pipeline. The deal centers on HLD-0915, a once-daily heterobifunctional small molecule now showing PSA50 and PSA90 responses in early-stage mCRPC patients, and a wider RIPTAC platform designed to “hold-and-kill” resistant tumors. Halda’s Phase I/II data showed a 31% PSA50 rate across all dosed patients and deeper responses in those completing two cycles, prompting J&J to pay up to secure both the lead and earlier-stage candidates. J&J framed the acquisition as a strategic expansion of its oncology toolbox to address drug resistance. RIPTAC (Regulated Induced Proximity Targeting Chimera) is a heterobifunctional modality that recruits a tumor-specific protein to an essential intracellular partner, provoking selective cancer-cell death; the term refers to the platform’s mechanism rather than an approved drug class. The transaction accelerates J&J’s access to oral small-molecule precision approaches targeting solid tumors and resistant disease.